Phase 1 safety and tolerability trial of levodopa eye drops for the treatment of short sightedness (myopia)

Project: Research

Project Details


This will be a first-in-human safety and tolerability trial of a novel ophthalmic solution for the treatment of the visual disorder myopia (short-sightedness). Myopia has been hypothesised to be driven by a reduction in dopamine levels within the eye. Therefore we have developed a novel ophthalmic formulation of a repurposed compound to stimulate ocular dopamine release. Before we can examine the efficacy of this compound at inhibiting myopia, this study will assess the safety and tolerability of levodopa as a reformulated eye drop solution.
Short titlePhase I safety trial
Effective start/end date19/03/2024/01/22


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.